Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Preece

Diagnostic Radiology Idaho Falls, ID Medical Doctor

NPI 1740434737 CMS profile 1308051

3100 Channing Way, Idaho Falls, ID 83404

Open in the dashboard

General payments

$4,430

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Preece of Idaho Falls, ID is reported in the CMS Open Payments database as having received $4,430 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $278 12
2024 General $527 21
2023 General $598 15
2022 General $730 12
2021 General $479 15
2020 General $147 8
2019 General $1,670 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Preece
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Stephen Preece were reported at $278. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Stephen Preece Diagnostic Radiology median Middle half National median
2019 $1,670 $108 $29–$318 $163
2020 $147 $65 $21–$252 $114
2021 $479 $92 $24–$292 $132
2022 $730 $104 $29–$294 $149
2023 $598 $110 $29–$337 $160
2024 $527 $113 $30–$356 $164
2025 $278 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $1,662 7 payments
  2. Boston Scientific Corporation $766 27 payments
  3. Inari Medical, Inc. $630 11 payments
  4. Abbott Laboratories $253 6 payments
  5. Terumo Medical Corporation $163 7 payments
  6. Cook Medical LLC $149 13 payments
  7. W. L. Gore & Associates, Inc. $142 7 payments
  8. Balt USA, LLC $138 1 payment
  9. Stryker Corporation $99 3 payments
  10. Varian Medical Systems, Inc. $94 2 payments
  11. Other $334 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,596 98 payments
  2. Travel and Lodging $834 1 payment
Products named General payments · program years 2019–2025
  1. Penumbra System Neurointervention $1,389 3 payments
  2. FLOWTRIEVER CATHETER, S $875 17 payments
  3. CT THROMBECTOMY SYSTEM KIT $509 7 payments
  4. Penumbra System Neurointervention $228 2 payments
  5. TheraSphere Y90 Glass Microspheres 10 GBq $184 6 payments
  6. ELUVIA $156 2 payments
  7. Prestige Coil System $138 1 payment
  8. Perclose ProGlide suture mediated closure system $89 1 payment
  9. SIR-Spheres Microspheres $80 6 payments
  10. PERCLOSE PROGLIDE $79 1 payment
  11. Other $1,194 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Diagnostic Radiology: 24

Drug cost

$52

Median for Diagnostic Radiology: $190

Branded share of claims

0%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 12 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 276 billing codes

Paid by Medicare

$130,455

Of which drugs: $243

Medicare patients

1,565

Average age 75

Services billed

4,258

788 women, 777 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 37%
Ischemic heart disease 34%
Chronic kidney disease 33%
Depression 30%
Heart failure 28%
Atrial fibrillation 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 1,275 $119

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record